Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1521-1540 of 3,900 trials

Spinal Cord Injury: TZ-161 Treatment Study

We are testing a new treatment for adults with early acute spinal cord injury to see if it is safe and effective compared to standard care. The study will also evaluate its effects on pain and recovery time.

Early Acute Spinal Cord Injury1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesNeurology

Cancer Treatment: Immune Therapy with Ultrasound

We are exploring a new treatment combining immune checkpoint inhibition therapy with focused ultrasound for cancer patients. This study aims to determine if this combination enhances the effectiveness of cancer treatment.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Acute Myeloid Leukemia: CD19 CAR-T Cell Therapy

We are studying the safety of a new CAR-T cell treatment for patients with refractory acute myeloid leukemia. This trial aims to see how well the treatment works and how long the CAR-T cells last in the body.

Recurrent Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Fast-Acting Insulins and Their Post-Meal Effects in Type 1 Diabetes

We are studying how different fast-acting insulins affect blood sugar levels after meals in people with type 1 diabetes. This research may help identify the best insulin for managing glucose and reducing oxidative stress.

Type 1 Diabetes1-2 yearsSafety phase (I)No PlaceboStandard MedicinesDiabetologyEndocrinology

Non-Small Cell Lung Cancer: New Treatment Combinations with Pembrolizumab

We are studying new investigational treatments combined with pembrolizumab and chemotherapy for patients with newly diagnosed resectable non-small cell lung cancer. The goal is to see how well these combinations work and their safety before surgery.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)Investigational MedicinesOncology

Cytisine vs. Nicotine Replacement Therapy for Smokers with Chronic Kidney Disease

We are studying whether cytisine can help nicotine-dependent patients with chronic kidney disease quit smoking more effectively than traditional nicotine replacement therapy. This trial will also look at any side effects from both treatments.

Nicotine DependenceChronic Kidney DiseaseMonitoring phase (IV)No PlaceboStandard MedicinesNephrologyPsychiatry

MOG Antibody-Associated Disease: Rozanolixizumab Study

We are studying whether Rozanolixizumab is effective and safe for adults with MOG antibody-associated disease. This research aims to provide insights into a potential new treatment for this condition.

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOG-AD)>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurology

Asthma Treatment: Atuliflapon Study

We are investigating whether Atuliflapon can improve symptoms in adults with moderate to severe uncontrolled asthma. This study compares its effects to a placebo to ensure safety and efficacy.

Moderate-to-Severe Uncontrolled Asthma3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyPulmonology

Ulcerative Colitis in Kids: Ozanimod Study

We are testing the oral medication ozanimod in children with moderately to severely active ulcerative colitis who haven't responded to other treatments. The goal is to see if it helps improve their symptoms and overall health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Indolent Non-Hodgkin's Lymphoma: EO2463 Cancer Vaccine

We are investigating a new cancer vaccine, EO2463, for patients with indolent Non-Hodgkin's Lymphoma. The trial aims to assess its safety and effectiveness alone and with other treatments.

Indolent Non-Hodgkin's Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Alpha-1 Antitrypsin Deficiency: BEAM-302 Treatment Study

We are exploring a new treatment for adults with Alpha-1 Antitrypsin Deficiency-related lung or liver disease. The study aims to evaluate its safety and effectiveness in improving health outcomes.

Alpha-1 Antitrypsin Deficiency (AATD)>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyPulmonology

B-cell Non-Hodgkin Lymphoma: JNJ-88998377

We are testing a new treatment for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. This study aims to find a safe dose and understand how the treatment works in humans.

Relapsed or Refractory B-cell Non-Hodgkin Lymphomas>2 yearsSafety phase (I)Oncology

Melanoma Treatment: Nivolumab with Isolated Limb Perfusion

We are studying whether combining nivolumab with isolated limb perfusion helps patients with in-transit melanoma metastases achieve better treatment responses. This trial will also look at safety and quality of life.

In-transit Metastasis of Malignant Melanoma1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteDermatologyOncology

Heart Attack Treatment: EVOLocumab Study

We are studying whether adding evolocumab to standard cholesterol management helps reduce serious heart-related events in patients recently hospitalized for a heart attack. This trial aims to improve outcomes for those affected by acute myocardial infarction.

High Cholesterol>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Relapsing Multiple Sclerosis: Remibrutinib vs. Ocrelizumab

We are studying whether remibrutinib is as effective and safe as ocrelizumab for people with relapsing multiple sclerosis after switching treatments. This trial will help us understand the best options for managing the disease.

Relapsing Multiple SclerosisConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal MedicineNeurology

ColiFin® Therapy for Adults with Bronchiectasis and Pseudomonas Infection

We are studying whether inhaled ColiFin® can improve health in adults with bronchiectasis who have a new asymptomatic Pseudomonas aeruginosa infection. The trial compares this treatment to standard care to see which is more effective.

Bronchiectasis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Advanced Non-Small Cell Lung Cancer: BNT116 Treatment

We are evaluating the safety and early effectiveness of BNT116, both alone and with other treatments, for patients with advanced non-small cell lung cancer. This study aims to find better options for managing this condition.

Advanced Non-Small Cell Lung Cancer>2 yearsSafety phase (I)OncologyPulmonology

TAVI Patients: Ticagrelor vs Aspirin Study

We are comparing the safety and effectiveness of Ticagrelor and Aspirin for patients after Transcatheter Aortic Valve Implantation. This study aims to see which treatment may lead to fewer serious health events and complications.

Aortic Stenosis>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Lobular Breast Cancer: Capivasertib and Fulvestrant Study

We are studying a new treatment combination for patients with high-risk lobular breast cancer to see if it improves cancer control and safety compared to standard therapy.

Invasive Lobular Breast Carcinoma≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Late-Onset Pompe Disease: SPK-3006 Infusion Study

We are testing a new intravenous treatment for adults with late-onset Pompe disease to evaluate its safety and potential benefits. This study will help us understand how well the treatment works and how it is tolerated.

Pompe Disease>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyGastroenterologyHematologyNeurology